Barrons.com • 7 days ago
Guggenheim's Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales: ...[When] looking at consensus estimates through 2020, there is a slight, though continuous, decline in overall revenue with EPS remaining largely flat, likely due to share repurchases. With approximately $16 billion in operating cash flow annually and more than $21 billion in cash and short-term assets on the balance sheet, Gilead has a good deal of capital to deploy to boost its revenues. Most questions we receive on Gilead regard what should it “buy.” What type of business development activity should Gilead engage in that will support possibly higher future revenues?
American City Business Journals • 28 days ago
Waltham drugmaker Tesaro wasted no time after announcing stellar late-stage trial results from its ovarian cancer drug before putting the resultant stock spike to good use with a $377 million stock offering. The secondary offering of 4.7 million shares by Tesaro (TSRO) valued at $81 each is the largest to be raised by a local biotech company since the sector began a significant selloff nearly a year ago. The last offering by a local drug developer that was of equal or greater size was a $450 million offering raised by Alnylam Pharmaceuticals (ALNY) in January 2015.
Zacks • 29 days ago
Shares of Tesaro, Inc. (TSRO) surged 108% after the company announced that its phase III trial, NOVA, on oncology drug niraparib successfully achieved the primary endpoint of progression-free survival (PFS).
Insider Monkey • 29 days ago
Stocks are trading in the green on Thursday as markets continue to steadily recover from the Brexit-triggered wild swings. However, investors remain selective as the future of the global economy is still dotted with uncertainties after UK’s exit from the European Union. Meanwhile, some stocks are worth watching closely today, including TESARO Inc (NASDAQ:TSRO), Stellar […]
TheStreet.com • 29 days ago
In most cases ovarian cancer recurs within two years after chemotherapy, but the Tesaro (TSRO) drug stops that, Dr. Marc Siegel explained on Fox Business today.
After hours: 93.260.02 (0.02%) as of 4:48 PM EDT
|Bid||92.72 x 100|
|Ask||99.84 x 200|
|52wk Range||29.51 - 94.48|
|Day's Range||91.18 - 93.83|
|Avg Vol (3m)||1,161,969|
As of 4:00 PM EDT. Market closed.